[go: up one dir, main page]

DK3786160T3 - Pyridinderivater og terapeutiske anvendelser deraf som trpc6-inhibitorer - Google Patents

Pyridinderivater og terapeutiske anvendelser deraf som trpc6-inhibitorer Download PDF

Info

Publication number
DK3786160T3
DK3786160T3 DK20197194.2T DK20197194T DK3786160T3 DK 3786160 T3 DK3786160 T3 DK 3786160T3 DK 20197194 T DK20197194 T DK 20197194T DK 3786160 T3 DK3786160 T3 DK 3786160T3
Authority
DK
Denmark
Prior art keywords
therapeutic uses
pyridine derivatives
trpc6
inhibitors
trpc6 inhibitors
Prior art date
Application number
DK20197194.2T
Other languages
English (en)
Inventor
Thierry Bouyssou
Dirk Gottschling
Niklas Heine
Keenan Lana Louise Smith
Michael D Lowe
Hossein Razavi
Christopher Ronald Sarko
Simon Surprenant
Hidenori Takahashi
Xinyuan Wu
Michael Robert Turner
Original Assignee
Boehringer Ingelheim Int
Hydra Biosciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int, Hydra Biosciences Llc filed Critical Boehringer Ingelheim Int
Application granted granted Critical
Publication of DK3786160T3 publication Critical patent/DK3786160T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK20197194.2T 2017-10-27 2018-10-25 Pyridinderivater og terapeutiske anvendelser deraf som trpc6-inhibitorer DK3786160T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762577883P 2017-10-27 2017-10-27
US201862628313P 2018-02-09 2018-02-09
EP18800513.6A EP3700902B8 (en) 2017-10-27 2018-10-25 Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors

Publications (1)

Publication Number Publication Date
DK3786160T3 true DK3786160T3 (da) 2022-08-22

Family

ID=64270818

Family Applications (2)

Application Number Title Priority Date Filing Date
DK18800513.6T DK3700902T3 (en) 2017-10-27 2018-10-25 Inhibitorer af trpc6
DK20197194.2T DK3786160T3 (da) 2017-10-27 2018-10-25 Pyridinderivater og terapeutiske anvendelser deraf som trpc6-inhibitorer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK18800513.6T DK3700902T3 (en) 2017-10-27 2018-10-25 Inhibitorer af trpc6

Country Status (31)

Country Link
US (4) US10889568B2 (da)
EP (2) EP3786160B1 (da)
JP (2) JP7217273B6 (da)
KR (2) KR20200125758A (da)
CN (1) CN111527078B (da)
AU (2) AU2018355743B2 (da)
CA (1) CA3078769A1 (da)
CL (2) CL2020001097A1 (da)
CY (1) CY1126109T1 (da)
DK (2) DK3700902T3 (da)
ES (2) ES2946274T3 (da)
FI (1) FI3700902T3 (da)
HR (2) HRP20230502T1 (da)
HU (2) HUE062460T2 (da)
IL (2) IL274039B (da)
LT (2) LT3786160T (da)
MX (1) MX387232B (da)
MY (1) MY202126A (da)
NZ (1) NZ763816A (da)
PE (1) PE20210154A1 (da)
PH (1) PH12020550503A1 (da)
PL (2) PL3786160T3 (da)
PT (2) PT3700902T (da)
RS (2) RS63535B1 (da)
SA (1) SA520411843B1 (da)
SG (2) SG11202003367TA (da)
SI (2) SI3700902T1 (da)
TW (2) TWI780246B (da)
UA (1) UA128474C2 (da)
WO (1) WO2019081637A1 (da)
ZA (1) ZA202002372B (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3786160T (lt) 2017-10-27 2022-09-26 Boehringer Ingelheim International Gmbh Piridino dariniai ir jų terapinis panaudojimas kaip trpc6 inhibitorių
US11485740B2 (en) * 2018-02-15 2022-11-01 Boehringer Ingelheim International Gmbh Inhibitors of TRPC6
WO2019161010A1 (en) * 2018-02-16 2019-08-22 Boehringer Ingelheim International Gmbh Inhibitors of trpc6
IL315313A (en) * 2018-08-24 2024-10-01 Xeniopro GmbH Aromatic molecules for use in the treatment of pathological conditions
US12156874B2 (en) * 2019-04-12 2024-12-03 Boehringer Ingelheim International Gmbh Inhibitors of TRPC6
WO2021079962A1 (ja) * 2019-10-24 2021-04-29 国立大学法人大阪大学 難聴の予防および／または治療用医薬組成物
EP4103245A1 (en) 2020-02-11 2022-12-21 Klinikum rechts der Isar der Technischen Universität München Administration of calcium channel trpc6 inhibitors using balloons, stents or other medical devices
AR121846A1 (es) 2020-04-16 2022-07-13 Teijin Pharma Ltd Derivado de arilo o heteroarilo
MX2022012923A (es) * 2020-04-16 2022-11-16 Boehringer Ingelheim Int Inhibidores de trpc6 para tratar afecciones respiratorias.
CN113105318B (zh) * 2021-02-23 2022-05-20 中山大学 一种2,2-二氟环丁烷-1-羧酸的制备方法及应用
JP2024538664A (ja) 2021-10-15 2024-10-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 敗血症を治療するためのｔｒｐｃ６阻害化合物
JP2025023360A (ja) * 2021-12-06 2025-02-17 国立大学法人 熊本大学 Ｔｒｐｃ６の発現を抑制する方法
TW202523305A (zh) 2023-08-18 2025-06-16 德商百靈佳殷格翰國際股份有限公司 用於治療局部節段性腎絲球硬化症之trpc6抑制劑

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991009594A1 (en) 1989-12-28 1991-07-11 Virginia Commonwealth University Sigma receptor ligands and the use thereof
PT100639A (pt) 1991-06-27 1993-09-30 Univ Virginia Commonwealth Metodo para o tratamento terapeutico com compostos que sao ligandos ao receptor sigma e compostos ai utilizados, nomeadamente derivados fenilalquil-amina, aminotetralina,piperazina e piperidina
EP0672031B1 (en) 1992-12-02 2003-03-12 Pfizer Inc. Catechol diethers as selective pde iv inhibitors
KR100660309B1 (ko) 1998-09-22 2006-12-22 아스텔라스세이야쿠 가부시키가이샤 시아노페닐 유도체
CA2401778C (en) 2000-02-29 2010-12-21 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
EP1301484A2 (en) 2000-07-20 2003-04-16 Neurogen Corporation Capsaicin receptor ligands
JP4186518B2 (ja) * 2001-06-15 2008-11-26 アステラス製薬株式会社 フェニルピリジン誘導体
WO2002102778A1 (en) 2001-06-15 2002-12-27 Yamanouchi Pharmaceutical Co., Ltd. Phenylpyridine carbonyl piperazine derivative
NI200300045A (es) 2002-04-26 2005-07-08 Pfizer Prod Inc Inhibidores de triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa.
DE10222291A1 (de) 2002-05-18 2003-11-27 Schlafhorst & Co W Faserbandzuführeinrichtung
CN1150176C (zh) 2002-05-22 2004-05-19 上海医药工业研究院 芳烷酮哌嗪衍生物及其应用
EP1809626A2 (en) 2004-10-13 2007-07-25 Neurogen Corporation Aryl substituted 8-azabicyclo[3.2.1]octane compounds as ligands of the melanin concentrating hormone receptor
DE102005044814A1 (de) * 2005-05-19 2006-11-23 Grünenthal GmbH Substituierte Sprio-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
AR056582A1 (es) 2005-10-28 2007-10-10 Lilly Co Eli COMPUESTOS DE PIRAZOLIL UREA CON ACTIVIDAD INHIBITORIA DE CINASA P38 Y FORMULACIoN FARMACÉUTICA QUE LO COMPRENDE
AU2006331882A1 (en) 2005-12-21 2007-07-05 Schering Corporation Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists
JP5019768B2 (ja) 2006-03-23 2012-09-05 独立行政法人科学技術振興機構 新規低分子化合物およびその製造方法
PE20090188A1 (es) 2007-03-15 2009-03-20 Novartis Ag Compuestos heterociclicos como moduladores de la senda de hedgehog
JP5082538B2 (ja) 2007-03-28 2012-11-28 Ｄｉｃ株式会社 ピペラジン化合物
EP2379524A1 (en) 2008-12-18 2011-10-26 Boehringer Ingelheim International GmbH Serotonin 5-ht2b receptor inhibitors
US20100234603A1 (en) 2009-03-13 2010-09-16 Xin Linghu Process for Making Substituted Aryl Sulfone Intermediates
US20110039850A1 (en) 2009-08-12 2011-02-17 Mhairi Copland Leukemia Treatment
CN102686579A (zh) 2009-10-09 2012-09-19 Irm责任有限公司 作为gpr119活性调节剂的化合物和组合物
RU2012125152A (ru) 2009-11-18 2013-12-27 Новартис Аг Способы и композиции, предназначенные для лечения солидных опухолей и других злокачественных новообразований
AU2010347233B2 (en) 2010-03-01 2015-06-18 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
ES2653966T3 (es) 2010-04-27 2018-02-09 Mitsubishi Tanabe Pharma Corporation Nuevo derivado de amida y su uso como medicina
SG185515A1 (en) 2010-05-13 2012-12-28 Amgen Inc Nitrogen heterocyclic compounds useful as pde10 inhibitors
PT2598483T (pt) 2010-07-29 2020-10-12 Rigel Pharmaceuticals Inc Compostos heterocíclicos de ativação de ampk e métodos de utilização dos mesmos
WO2012158784A2 (en) 2011-05-16 2012-11-22 Theodore Mark Kamenecka Modulators of the nuclear hormone receptor ror
JP5800786B2 (ja) 2011-10-26 2015-10-28 田辺三菱製薬株式会社 新規アミド誘導体を有効成分として含有する医薬組成物
US9139585B2 (en) 2011-10-31 2015-09-22 Merck Sharp & Dohme Corp. Inhibitors of the Renal Outer Medullary Potassium channel
CN103360343B (zh) 2012-03-30 2017-04-19 凯惠药业(上海)有限公司 一种哌嗪酰胺类化合物的制备方法
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
CN105308045B (zh) * 2013-05-27 2017-05-17 豪夫迈·罗氏有限公司 新的3,4‑二氢‑2h‑异喹啉‑1‑酮和2,3‑二氢‑异吲哚‑1‑酮化合物
US20150087673A1 (en) 2013-09-26 2015-03-26 Rigel Pharmaceuticals, Inc. Methods for using and biomarkers for ampk-activating compounds
EP3092235A2 (en) 2014-01-06 2016-11-16 Rhizen Pharmaceuticals S.A. Novel inhibitors of glutaminase
WO2015199206A1 (ja) * 2014-06-27 2015-12-30 塩野義製薬株式会社 Ｔｒｐｖ４阻害活性を有する６員環誘導体
UY36391A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen
MA41598A (fr) * 2015-02-25 2018-01-02 Constellation Pharmaceuticals Inc Composés thérapeutiques de pyridazine et leurs utilisations
WO2017066705A1 (en) 2015-10-14 2017-04-20 Aquinnah Pharmaceuticals, Inc. Compounds, compositions and methods of use against stress granules
CN107176927B (zh) 2016-03-12 2020-02-18 福建金乐医药科技有限公司 组蛋白去甲基化酶lsd1抑制剂
EP3429591B1 (en) 2016-03-16 2023-03-15 Kura Oncology, Inc. Substituted thieno[2,3-d]pyrimidine derivatives as inhibitors of menin-mll and methods of use
KR20190026771A (ko) 2016-06-20 2019-03-13 럿거스, 더 스테이트 유니버시티 오브 뉴 저지 치료 화합물
CN107540636A (zh) 2016-06-29 2018-01-05 成都贝斯凯瑞生物科技有限公司 一种含氮杂环衍生物及其应用
CN106317050B (zh) * 2016-08-24 2018-11-23 烟台大学 一种苯基噻唑衍生物及其制备方法与应用
JPWO2018159827A1 (ja) 2017-03-03 2020-01-09 国立大学法人京都大学 植物ステロイドホルモン（ブラシノライド）様活性をもつ非ステロイド化合物の創製
US10450303B2 (en) 2017-03-15 2019-10-22 Athenex, Inc. Biaryl piperidine amide compounds and methods of use thereof
LT3786160T (lt) * 2017-10-27 2022-09-26 Boehringer Ingelheim International Gmbh Piridino dariniai ir jų terapinis panaudojimas kaip trpc6 inhibitorių
EA202090900A1 (ru) * 2017-11-16 2020-10-02 Принсипиа Биофарма Инк. Ингибиторы иммунопротеасом
US11485740B2 (en) * 2018-02-15 2022-11-01 Boehringer Ingelheim International Gmbh Inhibitors of TRPC6
WO2019161010A1 (en) * 2018-02-16 2019-08-22 Boehringer Ingelheim International Gmbh Inhibitors of trpc6

Also Published As

Publication number Publication date
HRP20220991T1 (hr) 2022-11-11
CA3078769A1 (en) 2019-05-02
WO2019081637A1 (en) 2019-05-02
RS64271B1 (sr) 2023-07-31
JP7217273B2 (ja) 2023-02-02
TWI780246B (zh) 2022-10-11
US10800757B2 (en) 2020-10-13
NZ763816A (en) 2025-10-31
UA128474C2 (uk) 2024-07-24
HUE062460T2 (hu) 2023-11-28
ES2946274T3 (es) 2023-07-14
HUE059450T2 (hu) 2022-11-28
SG10202011632RA (en) 2021-01-28
PL3700902T3 (pl) 2023-09-04
AU2018355743A1 (en) 2020-05-14
JP7217273B6 (ja) 2024-02-08
SI3786160T1 (sl) 2022-11-30
CL2020002562A1 (es) 2021-01-15
KR102724066B1 (ko) 2024-10-30
IL277493A (en) 2020-11-30
US20190169168A1 (en) 2019-06-06
PL3786160T3 (pl) 2022-10-24
AU2020250185A1 (en) 2020-11-12
MX2020004283A (es) 2021-10-21
PT3786160T (pt) 2022-08-19
IL274039B (en) 2021-08-31
EP3700902A1 (en) 2020-09-02
IL274039A (en) 2020-06-30
PE20210154A1 (es) 2021-01-26
FI3700902T3 (fi) 2023-05-25
SI3700902T1 (sl) 2023-10-30
CY1126109T1 (el) 2023-11-15
MX387232B (es) 2025-03-18
US20210163449A1 (en) 2021-06-03
JP2021500390A (ja) 2021-01-07
EP3786160B1 (en) 2022-07-13
USRE49699E1 (en) 2023-10-17
TW201930294A (zh) 2019-08-01
SA520411843B1 (ar) 2024-01-27
PH12020550503A1 (en) 2021-03-22
ZA202002372B (en) 2023-10-25
AU2018355743B2 (en) 2022-04-14
CN111527078B (zh) 2023-06-02
RS63535B1 (sr) 2022-09-30
SG11202003367TA (en) 2020-05-28
MY202126A (en) 2024-04-05
PT3700902T (pt) 2023-05-30
JP2021008503A (ja) 2021-01-28
US20190169167A1 (en) 2019-06-06
HRP20230502T1 (hr) 2023-09-15
IL277493B (en) 2022-02-01
EP3700902B1 (en) 2023-03-08
TWI780511B (zh) 2022-10-11
ES2924933T3 (es) 2022-10-11
DK3700902T3 (en) 2023-05-22
CN111527078A (zh) 2020-08-11
KR20200125758A (ko) 2020-11-04
US10889568B2 (en) 2021-01-12
TW202120494A (zh) 2021-06-01
EP3786160A1 (en) 2021-03-03
KR20200095467A (ko) 2020-08-10
EP3700902B8 (en) 2023-08-02
LT3700902T (lt) 2023-06-26
JP6979502B2 (ja) 2021-12-15
LT3786160T (lt) 2022-09-26
BR112020007818A2 (pt) 2020-10-20
CL2020001097A1 (es) 2020-08-28
AU2020250185B2 (en) 2022-04-14

Similar Documents

Publication Publication Date Title
DK3786160T3 (da) Pyridinderivater og terapeutiske anvendelser deraf som trpc6-inhibitorer
DK3728254T3 (da) Benzylamin-substituerede pyridopyrimidinoner og derivater som sos1-inhibitorer
DK3658557T3 (da) Tyk2-inhibitorer og anvendelser deraf
DK3277681T3 (da) Imidazolonylquinoliner og deres anvendelse som atm-kinaseinhibitorer
DK3452463T3 (da) Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf
DK3328849T5 (da) 1,1,1-trifluor-3-hydroxypropan-2-yl-carbamat-derivater og 1,1,1-trifluor-4-hydroxybutan-2-yl-carbamat-derivater som magl-inhibitorer
DK3331894T3 (da) Nicotinamidmononukleotidderivater og anvendelser deraf
DK3389658T3 (da) Glycosidasehæmmere og anvendelser deraf
DK3149001T3 (da) Hidtil ukendte pyrazolopyrimidinderivater og deres anvendelse som MALT1-hæmmere
DK3250237T3 (da) Hemiasterlinderivater til konjugering og terapi
DK3357513T3 (da) Farmaceutisk sammensætning og anvendelse deraf
LT3452485T (lt) Arginazės inhibitoriai ir jų terapinis taikymas
DK3603620T3 (da) Liposomsammensætning og farmaceutisk sammensætning
DK3621694T5 (da) Lrrc33-inhibitorer og anvendelse heraf
DK3412660T3 (da) Sulfonamidderivat og farmaceutisk sammensætning indeholdende samme
DK3514153T3 (da) Pyrimidinforbindelse og farmaceutisk anvendelse deraf
DK3532459T3 (da) Lsd1-hæmmere og medicinske anvendelser deraf
DK3568396T3 (da) Hidtil ukendte amino-imidazopyridinderivater som janus kinase-inhibitorer og farmaceutisk anvendelse deraf
DK3268374T3 (da) Kv1.3-inhibitorer og deres medicinske anvendelse
DK3971177T3 (da) Aminopyridin-derivater og anvendelse deraf som selektive ALK-2-inhibitorer
DK3615502T3 (da) Terapeutiske forbindelser og fremgangsmåder
DK3280405T3 (da) Inhibitorer og anvendelser deraf
DK3797107T3 (da) Heterokondenserede pyridonforbindelser og anvendelse deraf som idh- hæmmere
DK3386956T3 (da) Fumagillolderivater og polymorfer deraf
DK3455216T3 (da) Pyridinylderivater, farmaceutiske sammensætninger og anvendelser deraf som aoc3-inhibitorer